This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sunshine Heart Welcomes Dr. Patrick Verta As Chief Medical Officer

Stocks in this article: SSH

EDEN PRAIRIE, Minn., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) announced that, effective today, Patrick Verta, MD, has joined the Company as Chief Medical Officer. Dr. Verta brings over 20 years of experience in the medical field with the majority of time spent in the cardiovascular field.  

Prior to joining Sunshine Heart, Dr. Verta served as Chief Medical Officer and Vice President of Clinical Affairs at Neomend, a medical device company that developed and commercialized the only FDA-approved sealant for air leaks following lung surgery via open thoracotomy. The company was acquired by Bard/Davol in October 2012. Before Neomend, he served as Medical Director of Clinical Research and Business Development at Abbott Vascular, where he played a critical role in the approval of several stent systems used in peripheral vascular disease, in particular carotid artery stenosis, renal artery stenosis, and peripheral Artery Disease (PAD). While at Abbott, Dr. Verta led the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the largest randomized carotid trial ever, enrolling over 2,500 patients and considered today to be the gold standard for carotid stenting trials. Prior to Abbott, Dr. Verta held the position of Endovascular Clinical Science and Biometrics Director at Guidant Corporation.

In addition to his experience driving clinical trials, he has co-authored seventeen manuscripts on novel medical device therapies in peer-review journals, and is credited with two patents in the data management and electronic data capture areas. Dr. Verta holds a Doctorate of Medicine from the Faculté de Médecine in Paris, France; as well as a Doctorate of Veterinary Medicine from the Ecole Nationale Vétérinaire d'Alfort, France. He also completed a Masters Degree in Biostatistics at the University of Paris.

"We are pleased and fortunate to welcome Dr. Verta to Sunshine Heart as Chief Medical Officer," said Dave Rosa, Sunshine Heart's CEO. "His experience conducting large, complex clinical trials will be essential as we continue to progress within both our U.S. pivotal trial, COUNTER HF; as well as our European post-market study, OPTIONS HF. In particular, we look forward to his contributions toward accelerating and managing prudent site selection and enrollment with regard to both clinical trials going forward."  

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs